Table 3. Prevalence of HGV-RNA and... | American Society of Hematology

Table 3.

Prevalence of HGV-RNA and HCV-RNA in Relation to Viral Safety of the Clotting Products Used

Clotting Product Used	No.	HGV-RNA Positive [95% CI]^*	HCV-RNA Positive [95% CI]
Group A
Non- or suboptimal viral inactivated product	236	39^† (17%) [12-22%]	168^‡ (71%) [65-77%]
Group B
Suboptimal and optimal viral inactivated product	26	13^† (50%) [30-70%]	7^‡ (27%) [12-48%]
Group C
Optimal viral inactivated product, recombinant product	32	2^† (6%) [1-21%]	0^‡ (0%) [0-11%]

Clotting Product Used	No.	HGV-RNA Positive [95% CI]^*	HCV-RNA Positive [95% CI]
Group A
Non- or suboptimal viral inactivated product	236	39^† (17%) [12-22%]	168^‡ (71%) [65-77%]
Group B
Suboptimal and optimal viral inactivated product	26	13^† (50%) [30-70%]	7^‡ (27%) [12-48%]
Group C
Optimal viral inactivated product, recombinant product	32	2^† (6%) [1-21%]	0^‡ (0%) [0-11%]

*95% CI = 95% confidence interval.

Chi-squared test for Trend, not significant.

Chi-squared test for Trend, P < .00001.